Home » » Stock Newsletters » Lebed.biz Alert – I may have discovered the next DNDN!
MBCI was also featured in the August edition of Biotechnology Focus, Canada’s oldest and most successful magazine serving the Canadian life science industry, in an article entitled "Tumour-Specific Markers: The Holy Grail of Cancer Diagnostics". To read the article go to: http://www.bioscienceworld.ca/TumourSpecificMarkersTheHolyGrailofCancerDiagnostics
Lebed.biz Alert – I may have discovered the next DNDN!
October 31, 2009 · Filed Under Stock Newsletters
Very rarely do I have biotechnology plays, but once in a while I discover an opportunity so big that I must bring it to you immediately…
I believe that I potentially could have discovered the next Dendreon Corp (DNDN), which made a run from $2.55 to $30.42 this year.
I know what you are thinking, there’s no way the company I am about to tell you about will ever become the next DNDN. While the odds of me being right may be low, remember that very few people gave DNDN a chance to succeed when it was $2.55.
I am confident that if you take the time to research this company this weekend, you will agree with me that the upside potential for this stock in the short-term is astronomical. The scientific community is beginning to go crazy over their technology and I believe it’s only a matter of time before the excitement spreads to the investment community!
The company is MabCure, Inc. and it trades under the symbol MBCI. It closed last week at $1.07.
MBCI’s vision is to change the perception of cancer as a largely incurable disease!
MBCI’s first goal is the development of simple diagnostic tests for the early detection of ovarian, prostate, colorectal and breast carcinomas. Each test will be based upon highly specific monoclonal antibodies (MAbs) against a given cancer which should be able to detect unique cancer markers in the blood, urine or other body fluids. Identifying the presence of disease before it disseminates beyond its original site should lead to a 90% cure rate of these cancer patients.
MBCI owns proprietary technology for the creation of unique and highly specific MAbs, which will be developed as diagnostic tools, imaging agents, and drugs to treat lethal cancers.
MBCI recently announced a major development milestone, with the creation of its MAbs against Colorectal Cancer, a devastating disease that could be treated effectively if diagnosed at an early stage. MBCI estimates the European and U.S. market potential for this product to each be in the billion dollar range.
I consider MBCI to be at the ground-floor right now. I am one of the first in the investment community to discover it, but word is quickly spreading in the scientific community and I believe it could spread throughout the investment community in the very near-future!
MBCI was featured in the September issue of GEN (Genetic Engineering & Biotechnology News), in an article entitled "Searching for Appropriate Cancer Biomarkers". To read this article go to: http://www.genengnews.com/articles/chitem.aspx?aid=3022
MBCI was also featured in the August edition of Biotechnology Focus, Canada’s oldest and most successful magazine serving the Canadian life science industry, in an article entitled "Tumour-Specific Markers: The Holy Grail of Cancer Diagnostics". To read the article go to: http://www.bioscienceworld.ca/TumourSpecificMarkersTheHolyGrailofCancerDiagnostics
MBCI was even featured in the June 4, 2009 edition of BioWorld Today, biotech’s most respected news source for over seventeen years. The cover story, written by Jennifer Boggs and titled “MabCure’s Revamped Hybridoma Approach Seeks Cancer Antigens,” describes the company’s “new take on a classic drug discovery technology,” detailing how MBCI is developing monoclonal antibodies against difficult-to-pinpoint tumor specific antigens (TSA) for the diagnostics market.
MBCI could one day provide physicians with novel antibodies and drugs that effectively attack only cancer cells while sparing normal tissue and minimize toxic side effects!
I strongly urge you to research MBCI this weekend! While all biotech plays are by nature highly speculative, this is a one biotech play that I am extremely confident about!
—–
My firm Lebed Biz LLC has been compensated by a third-party (Wall Street Grand LLC) $25,000 cash for a one-month MBCI investor relations contract. Never invest into a stock we discuss unless you can afford to lose your entire investment. For our full disclaimer go to: www.lebed.biz/disclaimer.htm
Jonathan Lebed
Lebed.biz
Staff
|
 |
For additional information on Penny Stocks and Hot Penny Stocks please visit here.
Comments
Leave a Reply